OrbiMed’s Xtant Medical Holdings XTNT Stock Holding History

OrbiMed’s Portfolio XTNT Stock Details XTNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-73,114,592	Closed	-$34.4M	–	125
2025 Q1	$34.4M	Hold	73,114,592	–	–	0.82%	33
2024 Q4	$32.4M	Hold	73,114,592	–	–	0.67%	42
2024 Q3	$49.4M	Hold	73,114,592	–	–	0.9%	32
2024 Q2	$46.1M	Hold	73,114,592	–	–	0.91%	34
2024 Q1	$85.5M	Hold	73,114,592	–	–	1.57%	19
2023 Q4	$82.6M	Hold	73,114,592	–	–	1.65%	18
2023 Q3	$80.4M	Hold	73,114,592	–	–	1.71%	19
2023 Q2	$68M	Hold	73,114,592	–	–	1.23%	30
2023 Q1	$46.6M	Hold	73,114,592	–	–	0.92%	38
2022 Q4	$48.3M	Hold	73,114,592	–	–	0.92%	41
2022 Q3	$52.6M	Buy	73,114,592 +170,674	+0.2%	+$93.5K	0.98%	38
2022 Q2	$37.9M	Hold	72,943,918	–	–	0.69%	46
2022 Q1	$49.6M	Buy	72,943,918 +70,424	+0.1%	+$46.1K	0.8%	39
2021 Q4	$40.8M	Hold	72,873,494	–	–	0.52%	54
2021 Q3	$80.9M	Hold	72,873,494	–	–	0.89%	34
2021 Q2	$119M	Hold	72,873,494	–	–	1.2%	28
2021 Q1	$172M	Buy	72,873,494 +70,422	+0.1%	+$150K	1.61%	18
2020 Q4	$87.1M	Buy	72,803,072 +63,554,394	+687%	+$81.8M	0.76%	42
2020 Q3	$7.62M	Hold	9,248,678	–	–	0.1%	115
2020 Q2	$8.32M	Buy	9,248,678 +41,666	+0.5%	+$38.2K	0.12%	107
2020 Q1	$6.17M	Hold	9,207,012	–	–	0.1%	100
2019 Q4	$14.7M	Hold	9,207,012	–	–	0.21%	72
2019 Q3	$26.1M	Hold	9,207,012	–	–	0.5%	51
2019 Q2	$27.6M	Hold	9,207,012	–	–	0.43%	56
2019 Q1	$28.1M	Hold	9,207,012	–	–	0.43%	58
2018 Q4	$14.8M	Hold	9,207,012	–	–	0.27%	77
2018 Q3	$35.4M	Hold	9,207,012	–	–	0.43%	65
2018 Q2	$51.1M	Hold	9,207,012	–	–	0.61%	49
2018 Q1	$72.6M	Buy	9,207,012 +8,810,813	+2,224%	+$58M	0.9%	38
2017 Q4	$272K	Buy	396,199 +356,579	+900%	+$2.81M	﹤0.01%	132
2017 Q3	$343K	Hold	39,620	–	–	﹤0.01%	139
2017 Q2	$314K	Hold	39,620	–	–	﹤0.01%	137
2017 Q1	$296K	Hold	39,620	–	–	﹤0.01%	135
2016 Q4	$261K	Hold	39,620	–	–	﹤0.01%	132
2016 Q3	$537K	Hold	39,620	–	–	0.01%	137
2016 Q2	$908K	Hold	39,620	–	–	0.01%	128
2016 Q1	$1.29M	Hold	39,620	–	–	0.01%	133
2015 Q4	$1.33M	Hold	39,620	–	–	0.01%	121
2015 Q3	$1.55M	Hold	39,620	–	–	0.02%	125
2015 Q2	$1.66M	Hold	39,620	–	–	0.01%	132
2015 Q1	$1.95M	Hold	39,620	–	–	0.02%	127
2014 Q4	$1.44M	Hold	39,620	–	–	0.01%	125
2014 Q3	$2.13M	Hold	39,620	–	–	0.02%	123
2014 Q2	$32.1M	Hold	39,620	–	–	0.38%	52
2014 Q1	$3.99M	Buy	39,620 +12,500	+46%	+$986K	0.05%	122
2013 Q4	$1.63M	Buy	27,120 +12,500	+85%	+$799K	0.02%	110
2013 Q3	$1.18M	Hold	14,620	–	–	0.02%	123
2013 Q2	$789K	Buy	+14,620	New	+$1.21M	0.02%	123

Other funds holding XTNT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed's XTNT Position: Q2 2025 in Review

OrbiMed sold out of Xtant Medical Holdings (XTNT) in Q2 2025, closing a stake of 73,114,592 shares — an estimated $34.4M sold.

OrbiMed first reported a position in XTNT in Q2 2013 and held it in 48 quarters. The position peaked at $172M in Q1 2021. 30 funds tracked by Wall St. Rank hold XTNT as of Q2 2025.

OrbiMed reported no remaining Xtant Medical Holdings position as of Q2 2025 after selling out during the quarter.
OrbiMed sold 73,114,592 Xtant Medical Holdings shares in Q2 2025, an estimated $34.4M.
OrbiMed first reported a position in Xtant Medical Holdings in Q2 2013 and held it in 48 quarters.
OrbiMed's Xtant Medical Holdings position peaked at $172M in Q1 2021.
30 funds tracked by Wall St. Rank held Xtant Medical Holdings as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.